Download PDF
Der Klinikarzt 2013; 42(11): 518-523
DOI: 10.1055/s-0033-1363600
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Pharmakotherapie bei Niereninsuffizienz – Fokus Chemotherapie, neue Antikoagulanzien, neue Antidiabetika

Drug therapy and impaired kidney function – Focus on anticancer drugs, new anticoagulants and antidiabetic drugs
René van Erp
1   Nephrologie, Medizinische Fakultät, Universität Ulm,
,
David Czock
2   Klinische Pharmakologie, Universitätsklinikum Heidelberg
,
Frieder Keller
1   Nephrologie, Medizinische Fakultät, Universität Ulm,
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2013 (online)

Also available at
    Permissions and Reprints

Die Pharmakotherapie bei Niereninsuffizienz spielt im klinischen Alltag vor dem Hintergrund steigender Lebenserwartung und zunehmendem Patientenalter eine immer wichtigere Rolle. Das Ziel einer adäquaten Dosisanpassung ist die Vermeidung von sowohl Über- als auch Unterdosierungen, sodass einerseits übermäßige Nebenwirkungen und andererseits mangelnde Therapieeffektivität vermieden werden. Eine korrekte Dosisanpassung erfordert die Beachtung sowohl pharmakokinetischer als auch pharmakodynamischer Regeln. Unter Kenntnis der renalen Eliminationsfraktionen von Muttersubstanz und relevanten Metaboliten sowie der individuellen GFR kann die erforderliche Dosisanpassung nach Dettli berechnet werden. Häufig besteht die Möglichkeit der Anwendung ähnlich wirksamer, aber im Rahmen der Niereninsuffizienz besser geeigneter Arzneimittel. Oft finden sich, sowohl in der Tumor- als auch in der Diabetes- oder Antikoagulationstherapie für definierte Substanzklassen Wirkstoffe, die von der Nierenfunktion unabhängig sind. Andernfalls sollte eine Dosisanpassung möglichst nach Zielspiegel berechnet werden.

Pharmacotherapy in renal impairment plays an increasingly important role in our daily clinical routine. The aim of an adequate dose adjustment is to avoid both, over- and under-dosing with consequences of excessive side effects or ineffectiveness of therapy. Adequate dose adjustment must consider pharmacokinetics as well as pharmacodynamics. Following the rules of Dettli, the general dose adjustment can be calculated by knowing the fraction of a drug that is eliminated by the renal route and the individual GFR of the patient. Often there are options of applying similar effective, but more suitable alternative drugs that are independent form kidney funciton. Frequently, such alternatives are even available within defined drug groups. Otherwise, dose adjustment is needed. Concentration dependent effects require adequate peak levels, whereas time dependent effects require adequate trough levels.

Key words

Kidney dysfunciton - pharmacokinetics - pharmacodynamics - anti cancer drugs - antidiabetics - anticoagulants
 

  • Literatur

  • 1 Keller F, Hartmann B. An easy to calculate equation to estimate GFR based on inulin clearance. Nephrol Dial Transplant author reply 2010; 25: 1346-1347
    CrossrefPubMedGoogle Scholar
  • 2 Li YF, Fu S, Hu W et al. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cance 2007; 17: 739-763
    PubMedGoogle Scholar
  • 3 Holstein A, Hammer C, Hahn M, Kulamadayil NS, Kovacs P. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and defencies of diabetes care in geriatric patients. Expert Opin Drug Saf 2010; 9: 675-681
    CrossrefPubMedGoogle Scholar
  • 4 Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996; 31: 111-119
    CrossrefPubMedGoogle Scholar
  • 5 Inoue T, Shibahara N, Miyagawa K et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003; 60: 90-95
    PubMedGoogle Scholar
  • 6 Idorn T, Knop FK, Jorgensen M et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. BMJ Open 2013; 3-3
    PubMedGoogle Scholar
  • 7 Chan JC, Scott R, Arjona Ferreira JC et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008; 10: 545-555
    CrossrefPubMedGoogle Scholar
  • 8 Nowicki M, Rychlik I, Haller H et al. Long-Term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairmant: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65: 1230-1239
    CrossrefPubMedGoogle Scholar
  • 9 Ito M, Abe M, Okada K et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011; 58: 979-987
    CrossrefPubMedGoogle Scholar
  • 10 Hoffmann P, Keller F. Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol 2012; 68: 757-665
    CrossrefPubMedGoogle Scholar
  • 11 Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency Hospitalizations for Adverse Drug Events in Older Americans. N Engl J Med 2011; 365: 2002-2012
    CrossrefPubMedGoogle Scholar
  • 12 Frost C, Nepal S, Wang J et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76: 776-786
    CrossrefPubMedGoogle Scholar